Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cempra Inc Announces Proposed Public Offering of Common Stock


Thursday, 13 Jun 2013 04:01pm EDT 

Cempra Inc announced that its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. The Company also intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering to cover over-allotments, if any. The Company intends to use the net proceeds from the offering to fund its planned IV-to-oral Phase 3 clinical trial of solithromycin in community acquired bacterial pneumonia (CABP), working capital and general corporate and administrative expenses. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Barclays, Stifel and Cowen and Company are acting as joint book-running managers for the offering. 

Company Quote

20.66
0.78 +3.92%
24 Dec 2014